EN
Alivus Life Sciences Limited Just Recorded A 6.2% Revenue Beat: Here's What Analysts Think
Shareholders of Alivus Life Sciences Limited (NSE:ALIVUS) will be pleased this week, given that the stock price is up 13% to ₹1,415 following its latest quarterly results. Results overall were respectable, with statutory earnings of ₹45.90 per share roughly in line with what the analysts had forecast. Revenues of ₹6.8b came in 6.2% ahead of analyst predictions. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Alivus Life Sciences after the latest results.
Taking into account the latest results, the most recent consensus for Alivus Life Sciences from four analysts is for revenues of ₹28.5b in 2027. If met, it would imply a modest 5.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to grow 11% to ₹60.60. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹28.4b and earnings per share (EPS) of ₹55.63 in 2027. So the consensus seems to have become somewhat more optimistic on Alivus Life Sciences' earnings potential following these results.
View our latest analysis for Alivus Life Sciences
The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 5.4% to ₹1,432. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Alivus Life Sciences, with the most bullish analyst valuing it at ₹1,624 and the most bearish at ₹1,330 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Alivus Life Sciences is an easy business to forecast or the the analysts are all using similar assumptions.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Alivus Life Sciences' rate of growth is expected to accelerate meaningfully, with the forecast 11% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 5.1% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Alivus Life Sciences is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Alivus Life Sciences following these results. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
With that in mind, we wouldn't be too quick to come to a conclusion on Alivus Life Sciences. Long-term earnings power is much more important than next year's profits. We have forecasts for Alivus Life Sciences going out to 2029, and you can see them free on our platform here.
Before you take the next step you should know about the 1 warning sign for Alivus Life Sciences that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.